Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low vs Conventional Dose Albumin in High Risk SBP
NCT06026267Recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of albumin (human) in spontaneous bacterial peritonitis (SBP) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Proportion of patients developing new AKI or having progression of AKI at Day 4. Started Oct 2023; status: recruiting.
02
Drugs
albumin (human)
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT06026267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026267.